Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
– Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month –
Ladenburg Thalmann analyst Ahu Demir downgrades Ayala Pharmaceuticals (OTC:ADXS) from Buy to Neutral.
Ladenburg Thalmann analyst Ahu Demir upgrades Advaxis (OTC:ADXS) from Neutral to Buy and announces $4 price target.
Ayala Pharmaceuticals Inc (NASDAQ: AYLA) and Advaxis Inc (OTC: ADXS) have announced a merger agreement.
Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing...
-SEC Filing
Updated data show a second partial response in Part B Overall response rate of 15.4% and disease control rate of 46% in Part...
